📈 Live Market Tracking
AI-Powered NSE Corporate Announcements Analysis
Anthem Biosciences to Host Q3FY26 Earnings Call on February 5, 2026
Anthem Biosciences Limited has issued a revised schedule for its earnings conference call to discuss the unaudited financial results for Q3 and the nine months ended December 31, 2025. The call is scheduled for Thursday, February 5, 2026, at 02:30 PM IST. This revision was necessitated by a non-functional joining link in the previous intimation. Senior management, including the MD & CEO and the CFO, will be present to discuss performance and answer questions.
Key Highlights
Earnings conference call scheduled for February 5, 2026, at 02:30 PM IST.
Focus on Unaudited Standalone and Consolidated Financial Results for Q3 and 9M FY26.
Management participants include MD & CEO Ajay Bhardwaj and CFO Gawir Baig.
Revised intimation provides corrected functional Diamond Pass registration links.
Call hosted by JM Financial Institutional Securities Limited.
💼 Action for Investors
Investors interested in the company's quarterly performance should use the revised link to join the call on February 5. No immediate action is required as this is a routine administrative update.
Alldigi Tech Declares 2nd Interim Dividend of INR 30 Per Share for FY 2025-26
Alldigi Tech Limited has declared a substantial second interim dividend of INR 30 per equity share for the financial year 2025-26, representing a 300% payout on its face value of INR 10. The company has established February 04, 2026, as the record date to identify eligible shareholders for this distribution. The dividend is scheduled to be paid to shareholders on or before February 20, 2026. This announcement was made alongside the approval of the company's unaudited financial results for the quarter and nine months ended December 31, 2025.
Key Highlights
Declared 2nd Interim Dividend of INR 30 per equity share of face value INR 10
Record date for determining shareholder eligibility is February 04, 2026
Dividend payment to be completed on or before February 20, 2026
Board approved Q3 and nine-month financial results ended December 31, 2025
Meeting concluded at 7:50 P.M. IST following the dividend and results approval
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date associated with the February 04 record date. Long-term investors should also review the accompanying Q3 financial results to assess the sustainability of such high payouts.
Alldigi Tech Declares 2nd Interim Dividend of ₹30 Per Share for FY 2025-26
Alldigi Tech Limited has declared a significant second interim dividend of ₹30 per equity share for the financial year 2025-26. The dividend is based on a face value of ₹10 per share, representing a 300% payout. The company has fixed February 04, 2026, as the record date to determine shareholder eligibility. This announcement was made alongside the approval of the company's unaudited financial results for the quarter and nine months ended December 31, 2025.
Key Highlights
Declared 2nd Interim Dividend of ₹30 per equity share for the financial year 2025-26
Record date for dividend eligibility is set for February 04, 2026
Dividend payment to be completed on or before February 20, 2026
Approved unaudited standalone and consolidated financial results for Q3 FY26
Dividend payout represents 300% of the face value of ₹10 per share
💼 Action for Investors
Investors seeking dividend income should ensure they hold shares before the ex-dividend date to qualify for the ₹30 payout. The substantial dividend indicates strong cash reserves and a shareholder-friendly capital allocation policy.
Nephroplus Subsidiary Acquires Philippines Dialysis Center for PHP 37.7 Million
Nephrocare Health Services Limited (Nephroplus) has announced that its step-down subsidiary in the Philippines has acquired a dialysis center in Cauayan. The deal involves an Asset Transfer Agreement with Dialysis Center of Cauayan Inc. for a total consideration of PHP 37,721,600. A separate Memorandum of Agreement ensures joint operations during the transition period for licensing and accreditation. This acquisition marks a strategic expansion of the company's international service network in Southeast Asia.
Key Highlights
Total acquisition cost of PHP 37,721,600 for assets in Cauayan, Philippines
Agreement signed with Dialysis Center of Cauayan Inc. (DCCI) on January 26, 2026
Includes a joint operation agreement for the interim period pending license transfers
Expansion executed through step-down subsidiary Nephrocare Health Care Services, Philippines Inc.
💼 Action for Investors
This expansion indicates a focus on growing the international footprint in high-demand markets. Investors should monitor the company's revenue contribution from international operations in upcoming quarterly reports.
Ravindra Energy targets 476 MWp solar capacity and 5,000 unit e-tractor plant by FY27
Ravindra Energy is executing a dual-growth strategy focusing on distributed solar power and heavy-duty electric mobility. The company plans to scale its solar capacity from 187 MWp to 476 MWp by FY27, largely through rural feeder solarization under the KUSUM scheme. Its electric mobility subsidiary, EIM, is establishing a 5,000-unit annual capacity manufacturing plant in Pune, expected to commission by June 2026. The company utilizes a Battery-as-a-Service (BaaS) model to drive adoption in the 55-tonne e-tractor segment, targeting port and industrial logistics.
Key Highlights
Solar operational capacity projected to grow ~2.5x from 187 MWp to 476 MWp by FY27.
New e-tractor manufacturing facility in Talegaon, Pune with 5,000 units p.a. capacity to be commissioned by June 2026.
Current e-mobility order book stands at 263 units with 125 units already sold as of December 2025.
Strategic battery swapping network expansion targeting 100 stations by FY29 to support heavy-duty EV corridors.
Maintains a 6-year exclusivity agreement for assembling and distributing heavy CVs (>18 tonnes) with CATL battery support.
💼 Action for Investors
Investors should track the execution of the Talegaon plant commissioning in mid-2026 and the pace of solar capacity additions. The stock represents a niche play on heavy-duty EV adoption and rural energy infrastructure with a strong 5-year price CAGR of 32%.
Share India Q3 FY26 Net Profit Up 8% to ₹88.8 Cr; Declares ₹0.40 Interim Dividend
Share India Securities reported a steady Q3 FY26 with consolidated revenue growing 8.7% YoY to ₹372 crore and net profit increasing 8% to ₹88.8 crore. Despite a decline in 9M FY26 performance where revenue fell 12.8%, the company maintained strong EBITDA margins of 42% in the third quarter. The board declared a third interim dividend of ₹0.40 per share, reflecting consistent shareholder returns. Strategic expansions into AIF, PMS, and fixed-income platforms through new subsidiaries signal a shift towards a more diversified financial services model.
Key Highlights
Q3 FY26 Revenue grew 8.7% YoY to ₹3,720 Mn with EBITDA margins at 42%
Net Profit for the quarter stood at ₹888 Mn, up 8% compared to the previous year
Board declared a 3rd interim dividend of ₹0.40 per share on a face value of ₹2
NBFC loan book reached ₹2,470 Mn with strong Net Interest Margins (NIM) of 4.63%
Strategic expansion into AIF and PMS via new subsidiary 'Share India Wealth Multiplier Solutions'
💼 Action for Investors
Investors should monitor the recovery in Q3 performance relative to the 9M figures and the company's aggressive diversification into high-yield segments like PMS and AIF. The stock remains a growth play in the fintech brokerage space with a consistent dividend track record.
Alldigi Tech Declares 2nd Interim Dividend of INR 30 Per Share for FY 2025-26
Alldigi Tech Limited has declared a significant second interim dividend of INR 30 per equity share for the financial year 2025-26, representing 300% of the face value. The announcement follows the board meeting held on January 27, 2026, where the company also approved its Q3 and nine-month financial results. The record date for dividend eligibility is set for February 04, 2026, with payments to be completed by February 20, 2026. This high payout reflects the company's commitment to returning capital to shareholders.
Key Highlights
Declared 2nd Interim Dividend of INR 30 per equity share of face value INR 10
Record date for dividend eligibility is fixed as February 04, 2026
Dividend payment to be completed on or before February 20, 2026
Board approved unaudited financial results for Q3 and nine months ended December 31, 2025
💼 Action for Investors
Investors seeking dividend income should ensure they hold the stock before the record date of February 04, 2026. Monitor the Q3 financial results for underlying business growth to assess the sustainability of such high payouts.
Vodafone Idea Q3 Net Loss Narrows to Rs 5,286 Cr; DoT Freezes AGR Dues at Rs 87,695 Cr
Vodafone Idea reported a narrowed consolidated net loss of Rs 5,286 crore for Q3 FY26 compared to a loss of Rs 6,609 crore in the same period last year. A critical regulatory update reveals that the Department of Telecommunications (DoT) has frozen AGR dues at Rs 87,695 crore, subject to reassessment, with a significantly relaxed payment schedule extending to 2041. While the company's net worth remains negative at Rs 87,744 crore, the restructured AGR payments provide a massive liquidity lifeline. Management is currently in discussions with banks to raise additional funds to support operations.
Key Highlights
Net loss narrowed to Rs 5,286 crore in Q3 FY26 from Rs 6,609 crore in Q3 FY25.
Service revenue grew slightly to Rs 11,307 crore, up from Rs 11,100 crore year-on-year.
DoT confirmed frozen AGR dues of Rs 87,695 crore, with a new payment plan requiring only Rs 124 crore annually until 2031.
Total deferred payment obligations include Rs 124,877 crore for spectrum and a book value of Rs 80,502 crore for AGR.
The company remains a going concern with a negative net worth of Rs 87,744 crore as of December 31, 2025.
💼 Action for Investors
The restructured AGR payment timeline is a game-changer for the company's survival, significantly reducing immediate cash outflow pressure. Investors should view this as a high-risk turnaround opportunity, focusing on upcoming bank fundraises and the final AGR reassessment outcome.
Alldigi Tech Declares 2nd Interim Dividend of ₹30 Per Share; Sets Record Date for Feb 4, 2026
Alldigi Tech Limited has declared a substantial second interim dividend of ₹30 per equity share for the financial year 2025-26. This announcement accompanied the approval of the company's unaudited financial results for the third quarter and nine months ended December 31, 2025. The company has established February 04, 2026, as the record date to identify eligible shareholders. The dividend is scheduled to be paid out to shareholders on or before February 20, 2026.
Key Highlights
Declared 2nd interim dividend of ₹30 per equity share with a face value of ₹10 each
Record date for dividend entitlement is fixed as February 04, 2026
Dividend payment to be completed on or before February 20, 2026
Board approved unaudited standalone and consolidated financial results for Q3 and 9M FY26
💼 Action for Investors
Investors interested in the dividend should ensure they hold the stock before the ex-dividend date (typically one day prior to the record date). The high dividend payout reflects strong cash flow and management's commitment to returning value to shareholders.
Siyaram Silk Mills Q3 FY26: Income Up 8.9% to ₹639 Cr, PAT Declines 8.7% to ₹42 Cr
Siyaram Silk Mills reported a moderate 8.9% YoY growth in total income for Q3 FY26, reaching ₹639 crores, though net profit declined by 8.7% to ₹42 crores due to margin pressure. The EBITDA margin contracted to 13.2% from 14.1% in the previous year, reflecting fluctuating demand post-festive season. For the nine-month period (9MFY26), the company showed stronger performance with a 15.3% revenue growth and a 5.7% increase in PAT. Additionally, the board declared a second interim dividend of ₹3 per share and continued its retail expansion with 7 new store openings in the quarter.
Key Highlights
Total income grew 8.9% YoY to ₹639 crores in Q3 FY26, while 9M FY26 income rose 15.3% to ₹1,782 crores.
Net profit for the quarter fell 8.7% YoY to ₹42 crores, with PAT margins dropping from 7.8% to 6.6%.
Declared a second interim dividend of ₹3 per equity share (150% of face value).
Retail footprint expanded with 7 new stores (2 ZECODE, 5 DEVO), bringing the total count to 42 outlets.
Revenue mix remains dominated by Fabric at 78%, followed by Garments at 15% and Yarn at 7%.
💼 Action for Investors
Investors should monitor the recovery in margins and the performance of the new retail formats (ZECODE and DEVO) as discretionary spending fluctuates. The interim dividend provides a yield cushion, but the PAT contraction in Q3 suggests a need for caution regarding rising operational costs.
MAS Financial Services to Attend Investor Conference in Singapore on Feb 5-6, 2026
MAS Financial Services Limited (MASFIN) has announced its participation in the JM Financial India Xchange Singapore 2026 conference. The company officials are scheduled to meet with various institutional investors and analysts on February 5 and February 6, 2026. These interactions will be conducted in both one-on-one and group formats in Singapore. The company has clarified that discussions will be limited to publicly available information and no unpublished price sensitive information will be shared.
Key Highlights
Participation in JM Financial India Xchange Singapore 2026 conference
Scheduled meetings on February 5 and February 6, 2026
Interaction formats include both one-on-one and group meetings
Engagement aimed at global institutional investors in Singapore
Compliance with SEBI Regulation 30 regarding investor disclosures
💼 Action for Investors
Investors should monitor for any updated investor presentations or management transcripts that may be released following these meetings. No immediate trading action is required as this is a routine corporate outreach event.
Ramkrishna Forgings Releases Q3 & 9M FY26 Earnings Call Audio Recording
Ramkrishna Forgings Limited has officially released the audio recording of its Q3 and 9M FY 2025-26 earnings conference call held on January 27, 2026. This filing ensures transparency by providing the public with access to management's discussion on the company's financial performance. The call follows the disclosure of results for the nine-month period ending December 31, 2025. Investors can use this resource to evaluate management's perspective on market conditions and operational efficiency.
Key Highlights
Audio recording for Q3 & 9M FY 2025-26 earnings call made available on January 27, 2026.
The call was held at 5:00 P.M. IST following the quarterly results announcement.
Disclosure made under Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.
Recording link is hosted on the company's official website for investor access.
💼 Action for Investors
Review the call recording to understand the management's outlook on the forging industry and specific revenue targets for FY26.
Sunteck Realty Reappoints Independent Directors Chaitanya Dalal and Mukesh Jain for 5-Year Terms
Sunteck Realty's Board has approved the reappointment of two Independent Directors, Mr. Chaitanya Dalal and Mr. Mukesh Jain, for a second consecutive five-year term starting September 18, 2026. Mr. Mukesh Jain brings nearly 49 years of experience in banking and real estate law, while Mr. Chaitanya Dalal is a veteran Chartered Accountant with extensive audit expertise. These reappointments, subject to shareholder approval, ensure continuity in the company's governance and strategic oversight. The board also reviewed the unaudited financial results for the quarter ended December 31, 2025, during the same meeting.
Key Highlights
Reappointment of Mr. Mukesh Jain and Mr. Chaitanya Dalal for a second 5-year term effective from September 18, 2026, to September 17, 2031
Mr. Mukesh Jain has 49 years of experience specializing in banking, real estate, and redevelopment laws
Mr. Chaitanya Dalal is a practicing CA and former Head of Accountancy at Bhavan’s College with expertise in statutory and tax audits
The board concurrently approved the Unaudited Financial Results for the quarter and nine months ended December 31, 2025
Both directors are confirmed to be not debarred from holding office by any SEBI order or authority
💼 Action for Investors
This is a routine governance update ensuring board stability; investors should focus more on the Q3 FY26 financial results mentioned in the announcement for operational performance.
Jaro Institute to Host Q3 FY26 Earnings Call on January 30, 2026
Jaro Institute of Technology Management and Research Limited has scheduled its Q3 FY26 earnings conference call for January 30, 2026, at 2:00 PM IST. The session will be led by Chairman & Managing Director Sanjay Namdeo Salunkhe and CEO Ranjita Raman. This routine disclosure under SEBI Regulations provides a platform for management to discuss quarterly financial performance with analysts and institutional investors. Access is provided via universal dial-in numbers +91 22 6280 1437 and +91 22 7115 8825.
Key Highlights
Earnings call scheduled for Friday, January 30, 2026, at 14:00 IST.
Management representation includes CMD Sanjay Namdeo Salunkhe and CEO Ranjita Raman.
Universal dial-in numbers provided: +91 22 6280 1437 and +91 22 7115 8825.
Meeting to be conducted virtually with a pre-registration option available for participants.
💼 Action for Investors
Investors should attend or review the transcript of the call to understand management's guidance on growth and margin sustainability. Focus on updates regarding student enrollment trends and new institutional partnerships.
RPG Life Sciences Q3 FY26 Revenue Up 4.2% Y-o-Y to Rs 180 Cr; EBITDA Margin at 24%
RPG Life Sciences reported a steady performance for Q3 FY26 with revenue growing 4.2% Y-o-Y to Rs 180.0 crores. The company maintained a healthy EBITDA margin of 24.0%, reflecting operational efficiency despite a marginal Q-o-Q revenue dip from Rs 181.7 crores. Notably, the Domestic Formulations segment grew by 11.8% in the first nine months of FY26, significantly outperforming the Indian Pharmaceutical Market (IPM) growth of 8.2%. Overall 9M FY26 revenue reached Rs 530.6 crores, up from Rs 510.3 crores in the previous year.
Key Highlights
Q3 FY26 Revenue grew 4.2% Y-o-Y to Rs 180.0 crores vs Rs 172.7 crores in Q3 FY25
EBITDA margin remained robust at 24.0% for the quarter
Domestic Formulations business grew 11.8% in 9M FY26, outperforming the IPM growth of 8.2%
9M FY26 total revenue reached Rs 530.6 crores, a 4.0% increase Y-o-Y
Q-o-Q revenue saw a slight decline from Rs 181.7 crores to Rs 180.0 crores
💼 Action for Investors
Investors should take note of the company's consistent ability to outperform the domestic pharma market growth and maintain high margins. The stock remains a solid mid-cap pharma play focused on branded formulations and operational efficiency.
Sammaan Capital Reports Timely Interest Payment of ₹8.71 Lakhs on NCDs
Sammaan Capital Limited, formerly known as Indiabulls Housing Finance, has successfully made timely interest payments on two series of Secured Redeemable Non-convertible Debentures (NCDs). The total interest disbursed amounted to approximately ₹8.71 lakhs for the monthly cycle ending January 2026. Notably, the payments were processed on January 27, 2026, one day ahead of the scheduled due date. This routine disclosure confirms the company's adherence to its debt servicing obligations for its listed public issues.
Key Highlights
Total interest payment of ₹8.71 lakhs made across two ISINs (INE148I07LU4 and INE148I07LV2)
Payments were executed on January 27, 2026, ahead of the January 28 due date
The interest frequency for these specific NCDs is monthly
The company maintains compliance with Regulation 57 of SEBI (LODR) Regulations
Issue sizes for the affected NCD series are ₹26.00 lakhs and ₹1,119.54 lakhs respectively
💼 Action for Investors
This is a routine regulatory filing indicating healthy debt servicing; no immediate action is required for equity or debt holders. Investors should focus on upcoming quarterly financial results for broader performance trends.
Belrise Industries to Hold Q3 & 9M FY26 Earnings Call on February 2, 2026
Belrise Industries Limited has scheduled its earnings conference call for Monday, February 2, 2026, at 9:30 AM IST to discuss the Q3 and 9M FY26 financial results. This follows the Board of Directors meeting on January 31, 2026, where the financial statements for the quarter ended December 31, 2025, will be officially considered and approved. The call will feature top management including the Managing Director, CFO, and heads of strategy and marketing. Investors can participate via pre-registration or through international dial-in numbers provided for the US, UK, Singapore, and Hong Kong.
Key Highlights
Board meeting to approve Q3 FY26 results is scheduled for January 31, 2026
Earnings conference call confirmed for February 2, 2026, at 9:30 AM IST
Key participants include MD Shrikant Badve, CFO Rahul Ganu, and CMO Sunil Kulkarni
International access numbers provided for investors in USA, UK, Singapore, and Hong Kong
💼 Action for Investors
Investors should monitor the results release on January 31 and attend the conference call to understand management's outlook on the automotive engineering sector.
DevX Launches 3.15 Lakh Sq. Ft. Managed Office Campus in Ahmedabad; 95% Pre-Leased
Dev Accelerator Limited (DevX) has launched 'Capital One' in Ahmedabad, which is the largest managed office campus in an Indian Tier II city, spanning 3.15 lakh sq. ft. The facility has achieved a significant 95% occupancy rate prior to its official launch, driven by demand from technology, accounting, and media firms. This expansion brings the company's total managed area to approximately 8.6 lakh sq. ft. across 12 cities. The high pre-leasing rate indicates strong demand and execution capability in emerging business hubs.
Key Highlights
Launched 'Capital One' in Ahmedabad, a 3.15 lakh sq. ft. managed office campus across 19 floors.
Achieved 95% occupancy pre-launch, demonstrating robust demand in Tier II markets.
Company now operates 28 centers across 12 cities with approximately 13,604 seats.
Total area under management has reached approximately 8.6 lakh sq. ft. nationally.
💼 Action for Investors
The 95% pre-leasing occupancy significantly de-risks this expansion and validates the company's growth strategy in Tier II cities. Investors should monitor the scalability of this 'Landowner First' model as a driver for future revenue growth.
Ixigo Schedules Virtual Meeting with Baillie Gifford & Co on January 30, 2026
Le Travenues Technology Limited (Ixigo) has announced a virtual meeting with Baillie Gifford & Co. scheduled for January 30, 2026. The meeting will involve Portfolio Manager Ben Durrant and will focus on the company's financial performance for the quarter and nine months ended December 31, 2025. The company intends to use the investor presentation previously submitted to the exchanges on January 22, 2026. This interaction highlights ongoing engagement with significant global institutional investors following their recent earnings release.
Key Highlights
Virtual meeting scheduled with Baillie Gifford & Co. on January 30, 2026, at 02:30 P.M. IST
Discussion will cover standalone and consolidated financial results for Q3 and 9M ended December 31, 2025
Company will use the existing investor presentation filed under letter LTTL/L&S/2025-26/01/13
Meeting participant identified as Ben Durrant, Portfolio Manager at Baillie Gifford & Co.
💼 Action for Investors
No immediate action is required as this is a routine investor engagement. Investors should review the Q3 FY26 presentation available on the company website to understand the data being discussed with institutional funds.
Entero Healthcare Subsidiary Faces 3-Day License Suspension; Revenue Impact Rs 1.88 Million
Entero Healthcare Solutions' wholly-owned subsidiary, Atreja Healthcare Solutions Private Limited, has been ordered to temporarily suspend its drug licenses for three days. The suspension, issued by the Karnal Zone Licensing Authority, will be effective from January 30, 2026, to February 1, 2026. This administrative action follows contraventions of the Drugs and Cosmetics Act, 1940. The company anticipates a minor revenue loss of approximately Rs 1.88 million, which is not expected to materially impact the overall financial health of the listed entity.
Key Highlights
3-day temporary suspension of drug licenses for subsidiary Atreja Healthcare Solutions.
Suspension period scheduled from January 30, 2026, to February 1, 2026.
Estimated potential revenue loss of approximately Rs 1.88 million during the suspension.
Action taken by Senior Drugs Control Officer, Karnal Zone, for violations of Drugs and Cosmetics Rules 64 and 65(5).
Management confirms no material impact on the overall operations of Entero Healthcare Solutions.
💼 Action for Investors
This is a minor regulatory event with negligible financial impact on the consolidated entity. Investors should monitor if such compliance lapses become frequent across other subsidiaries.